Serca–VivarRios CaBI19 vaccine: Difference between revisions
Jump to navigation
Jump to search
m (page inactive; removing tag) |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{Region icon MusgorociaSC}} | {{Region icon MusgorociaSC}} | ||
{{Infobox product | {{Infobox product | ||
| title = Serca–VivarRios CaBI19 vaccine | | title = Serca–VivarRios CaBI19 vaccine | ||
| Line 15: | Line 14: | ||
| last production = | | last production = | ||
| models = CabiShield | | models = CabiShield | ||
| website = | | website = {{url|https://www.cabishield.cs|cabishield.cs}} | ||
| notes = | | notes = | ||
}} | }} | ||
Latest revision as of 12:15, 31 July 2023
 | |
| Type | Toxoid-based vaccine |
|---|---|
| Inventor | Serca Circuit University VivarRios Pharmaceuticals |
| Manufacturer | VivarRios Pharmaceuticals |
| Available | In Phase III trials in Carloso and some other countries |
| Models made | CabiShield |
| Website | cabishield.cs |
The Serca–VivarRios CaBI19 vaccine, also sold under the brand name CabiShield, is a Carlosian toxoid-based vaccine being developed against the Clostroides abaddoni bacterial infection 2019 (CaBI19) disease. It is an evolution of efforts to develop a vaccine for Clostridioides difficile infection (CDI). Interim results indicate an efficacy of 95% against CaBI19.
Notes
See also